Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications
- PMID: 40190666
- PMCID: PMC11970494
- DOI: 10.34172/apb.43306
Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications
Abstract
Purpose: It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective.
Methods: Literature review and re-thinking.
Results: This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond.
Conclusion: Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.
Keywords: Drug repurpose; Targeted therapy; Tissue agnostic approval.
©2024 The Author (s).
Conflict of interest statement
None declared.
Similar articles
-
FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.Target Oncol. 2023 Sep;18(5):777-792. doi: 10.1007/s11523-023-00982-6. Epub 2023 Jul 21. Target Oncol. 2023. PMID: 37477750
-
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.Ann Oncol. 2024 Nov;35(11):936-953. doi: 10.1016/j.annonc.2024.07.730. Epub 2024 Aug 25. Ann Oncol. 2024. PMID: 39187421
-
Site-agnostic biomarker-guided oncology drug development.Expert Rev Mol Diagn. 2020 Jun;20(6):583-592. doi: 10.1080/14737159.2020.1702521. Epub 2019 Dec 12. Expert Rev Mol Diagn. 2020. PMID: 31813299
-
The evolving landscape of tissue-agnostic therapies in precision oncology.CA Cancer J Clin. 2024 Sep-Oct;74(5):433-452. doi: 10.3322/caac.21844. Epub 2024 May 30. CA Cancer J Clin. 2024. PMID: 38814103 Review.
-
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?Clin Cancer Res. 2019 Jun 1;25(11):3210-3219. doi: 10.1158/1078-0432.CCR-18-3694. Epub 2019 Jan 22. Clin Cancer Res. 2019. PMID: 30670489 Review.
References
-
- Stuart DD, Guzman-Perez A, Brooijmans N, Jackson EL, Kryukov GV, Friedman AA, et al. Precision oncology comes of age: designing best-in-class small molecules by integrating two decades of advances in chemistry, target biology, and data science. Cancer Discov. 2023;13(10):2131–49. doi: 10.1158/2159-8290.cd-23-0280. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources